Skip to content
10-Q

Quarterly Report

Avalyn Pharma Inc. AVLN

0001193125-26-254623

← back to feed
Filed
Jun 3, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2026 · Jun 2, 2026 44.33M sh
Shares Diluted Q1 2026 · Mar 31, 2026 1.23M sh
Shares Diluted Q1 2026 · Mar 31, 2025 276.79K sh
Capex Q1 2026 · Mar 31, 2026 $318K
Capex Q1 2026 · Mar 31, 2025 $8K
Operating Cash Flow Q1 2026 · Mar 31, 2026 −$29.89M
Operating Cash Flow Q1 2026 · Mar 31, 2025 −$19.28M
Long Term Debt Q1 2026 · Mar 31, 2026 $14.81M
Long Term Debt Q1 2026 · Dec 31, 2025 $0
Cash And Equivalents Q1 2026 · Mar 31, 2026 $92.31M
Cash And Equivalents Q1 2026 · Dec 31, 2025 $52.32M
Stockholders Equity Q1 2026 · Mar 31, 2026 −$264.25M
Stockholders Equity Q1 2026 · Dec 31, 2025 −$238.66M
Stockholders Equity Q1 2026 · Mar 31, 2025 −$191.57M
Stockholders Equity Q1 2026 · Dec 31, 2024 −$174.52M
Current Liabilities Q1 2026 · Mar 31, 2026 $11.79M
Current Liabilities Q1 2026 · Dec 31, 2025 $14.09M
Total Liabilities Q1 2026 · Mar 31, 2026 $27.69M
Total Liabilities Q1 2026 · Dec 31, 2025 $15.32M
Current Assets Q1 2026 · Mar 31, 2026 $129.99M
Current Assets Q1 2026 · Dec 31, 2025 $143.56M
Total Assets Q1 2026 · Mar 31, 2026 $135.66M
Total Assets Q1 2026 · Dec 31, 2025 $148.88M
Eps Diluted Q1 2026 · Mar 31, 2026 −$21.83
Eps Diluted Q1 2026 · Mar 31, 2025 −$63.24
Eps Basic Q1 2026 · Mar 31, 2026 −$21.83
Eps Basic Q1 2026 · Mar 31, 2025 −$63.24
Sga Expense Q1 2026 · Mar 31, 2026 $5.02M
Sga Expense Q1 2026 · Mar 31, 2025 $3.4M
Rd Expense Q1 2026 · Mar 31, 2026 $22.89M
Rd Expense Q1 2026 · Mar 31, 2025 $15.32M
Net Income Q1 2026 · Mar 31, 2026 −$26.87M
Net Income Q1 2026 · Mar 31, 2025 −$17.5M
Operating Income Q1 2026 · Mar 31, 2026 −$27.91M
Operating Income Q1 2026 · Mar 31, 2025 −$18.72M